A risk benefit assessment of amifostine in cytoprotection

Drug Safety

Volumn 21, Issue 5, 1999, Pages 367-387

  Mabro, May ^a   Faivre, Sandrine ^b   Raymond, Eric ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PERFOSFAMIDE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

AREA UNDER THE CURVE; BONE MARROW RESCUE; CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DNA ADDUCT; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOXICITY; HEART MUSCLE CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPOTENSION; KIDNEY CELL; MUCOSA CELL; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NERVE CELL; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; REVIEW; RISK BENEFIT ANALYSIS; SECOND CANCER; THROMBOCYTOPENIA; VOMITING;

AMIFOSTINE; ANIMALS; BONE MARROW; DRUG INTERACTIONS; HUMANS; RADIATION-PROTECTIVE AGENTS; RISK FACTORS;

EID: 0032729870     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921050-00003     Document Type: Review

References (78)

1. 1. Schuchter LM, Meropol N, Glick JH. Radiation and chemotherapy protectors. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia, New York: Lippincott-Raven, 3087-92
2. 2. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52
3. 3. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27
4. 4. Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. J Nat Cancer Inst 1969; 42: 331-5
5. 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 1976; 68: 284-91
6. 6. Utley JF, Seaver N, Newton GL, et al. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Rad Oncol Biol Phys 1984; 10: 1525-8
7. 7. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980; 41: 1519-24
8. 8. Calabro-Jones PM, Fahey RC, Smoluk GD, et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Rad Biol 1985; 47: 23-7
9. 9. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988; 48: 3634-40
10. 10. Yang JL, Fernandes DJ, Speicher L, et al. Biochemical determinants of the cytoprotective effect of amifostine [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A1725
11. 11. Fichtner I, Lemm M, Becker M, et al. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs 1997; 8: 174-81
12. 12. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Int J Rad Oncol Biol Phys 1986; 12: 1501-4
13. 13. Treskes M, Nijtmans LG, Fichtinger-Schepman AM, et al. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adduct in vitro in comparison to the effect of thiosulfate and diethyldithiocarbamate. Biochem Pharmacol 1992; 43: 1013-9
14. 14. Treskes M, Boven E, Holwerda U, et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992; 52: 2257-60
15. 15. Korst AEC, Boven E, van der Sterre MLT, et al. Influence of single and multiple dose of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Br J Cancer 1997; 75: 1439-46
16. 16. Korst AEC, van der Sterre MLT, Gall HE, et al. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1998; 4: 331-6
17. 17. Korst AEC, van der Sterre MLT, Eeltink CN, et al. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. Clin Cancer Res 1997; 3: 697-703
18. 18. Van der Vijgh WJ, Stieltjes H, Dijkstra RJ, et al. Influence of amifostine (Ethyol) on the pharmacokinetics of epirubicin [abstract]. Proc Annu Meet Am Assoc Cancer Res 1997; 38: A18
19. 19. Schuller J, Czejka M, Pietrzak C, et al. Doxorubicin pharmacokinetics is altered by the cytoprotective agent amifostine [abstract]. Proc Annu Meet Am Assoc Cancer Res 1996; 37: A1221
20. 20. Thompson DC, Holbrook DJ, Chaney SG. Effects of WR-2721 on ormaplatin biotransformations in tumor-bearing Fisher 344 rats [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A2386
21. 21. Thompson DC, Holbrook DJ, Chaney SG. HPLC characterization of organ-specific biotransformation of ormaplatin in tumor-bearing rats protected with WR-2721 [abstract]. Proc Annu Meet Am Assoc Cancer Res 1994; 35: A2621
22. 22. Yuhas JM, Spellman JM, Jordan SW, et al. Treatment of tumors with the combination of WR-2721 and cis-dichlorodiamineplatinum or cyclophosphamide. Br J Cancer 1980; 42; 574-85
23. 23. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3: 211-6
24. 24. Yuhas JM. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979; 63: 971-6
25. 25. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330-1
26. 26. Treskes M, Boven E, van de Loosdrecht AA, et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 1994; 30A: 183-7
27. 27. Taylor CW, Wang LM, List AF, et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumor cells is maintained. Eur J Cancer 1997; 33: 1693-8
28. 28. Wittenkeller J, Bittner G, Schiller JH. Amifostine (WR-2721) enhances cisplatin/vinblastine effect on non-small cell lung carcinoma cells in vivo but not in vitro [abstract]. Proc Annu Meet Am Assoc Cancer Res 1994; 35: A2298
29. 29. Dunn TA, Schmol HJ, Grünwald V, et al. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs 1996; 7: 795-9
30. 30. Alberts DS, Speicher LA, Krutzsch M, et al. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer 1996; 32A Suppl. 4: 17-20
31. 31. Fulda S, Oster W, Berthold F. Effects of WR-2721 (omifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anticancer Drugs 1997; 8: 34-41
32. 32. Kemp G, Rose P, Lurain J, et al. Amifostine pre-treatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12
33. 33. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134-40
34. 34. Anderson H, Mercer V, Thatcher N. A phase III randomised trial of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small cell lung cancer (NSCLC), [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A1787
35. 35. Betticher DC, Anderson H, Ranson M, et al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Br J Cancer 1995; 72: 1551-5
36. 36. Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584-8
37. 37. Avites A, Diaz-Maquco JC, Talavera A, et al. Bone marrow protection with amifostine in the treatment of high risk malignant lymphoma. Eur J Cancer 1997; 33: 1323-5
38. 38. Brizel D, Sauer R, Wannenmacher M, et al. Randomized phase III trial of radiation ± amifostine in patients with head and neck cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A1487
39. 39. Büntzel J, Schuth J, Küttner K, et al. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998; 6: 155-60
40. 40. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69: 2820-5
41. 41. Poplin EA, LoRusso P, Lokich JJ, et al. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994; 33: 415-9
42. 42. Planting AS, Vermorken JB, Catimel G, et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients with head and neck cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A887
43. 43. Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single dose WR-2721, S-2-(aminopropylamino) ethylphosphorothioic acid. Cancer Treat Rep 1986; 70: 1389-93
44. 44. Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR-2721 in carcinoma of the uterine cervix: a New York Gynecologie Group Study. J Clin Oncol 1993; 11: 1511-6
45. 45. Klastersky J, Sculier JP, Ravez P, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986; 4: 1780-6
46. 46. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11: 873-8
47. 47. Sculier JP, Klastersky J, Giner V, et al. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 353-9
48. 48. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-81
49. 49. Dentino M, Luft FC, Nahm Yum M, et al. Long term effect of cis-diamminedichloride platinum on renal function and structure in man. Cancer 1978; 41: 1274-81
50. 50. Fjeldhorg P, Sorensen J, Helkjaer PE. The long term effect of cisplatin on renal function. Cancer 1986; 58: 2214-7
51. 51. Glover D, Glick JH, Weiler C, et al. WR-2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5: 574-8
52. 52. Capizzi RL, Schefller BS, Oster W, et al. Amifostine reduces cumulative cisplatin nephrotoxicty [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S123
53. 53. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14: 1913-21
54. 54. Tannehil SP, Mehta MP, Larson M, et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: results of a phase II trial. J Clin Oncol 1997; 15: 2850-7
55. 55. Breier S, Lebedinsky C, Peleryest L, et al. Amifostine, cisplatin and vinorelbine in non-small cell lung cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A1664
56. 56. Demchak PA, Mier JW, Robert BJ, et al. Intereukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9: 1821-30
57. 57. De la Garza SJ. Cisplatin, radiotherapy, and amifostine (WR-2721) in advanced and previously untreated cervival cancer: phase II study [abstract]. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A1317
58. 58. Wasserman TH, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trial 1981; 4: 3-6
59. 59. List AF, Heaton R, Glinsman-Gibson B. Amifostine is a potent stimulant of hematopoietic progenitors [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A1732
60. 60. List AF, Heaton R, Glinsmann-Gibson B, et al. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow [abstract]. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A1403
61. 61. Bokemeyer C, Hartmann JT, Fels L, et al. Amifostine protects against early cisplatin-induced renal damage and enhances CD34+ cell numbers for PBSC collection [abstract]. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A166
62. 62. Wooley PV, Ayoob MJ, Smith FP, et al. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. J Clin Oncol 1983; 1: 198-203
63. 63. List AF, Brasfield F, Heaton R , et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364-9
64. 64. Vandenberghe EA, Goldstone AH. Autologous stem cell transplants in lymphomas. Ann Med 1996; 28 (2): 137-43
65. 65. Douay L, Hu C, Giarratana MC, et al. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 1994; 21 Suppl. 11: 16-20
66. 66. Douay L, Hu C, Giarratana MC, et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 1995; 86: 2849-55
67. 67. Shpall EJ, Stemmer SM, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132-7
68. 68. Van der Hoop RG, van der Burg MEL, len Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66: 1697-702
69. 69. Mollmann JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61: 2192-5
70. 70. Mitchell RB. Amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small-cell lung cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A1906
71. 71. Gelmon K, Tomiak E, Tolcher A, et al. Randomized trial of high dose paclitaxel plus/minus amifostine in recurrent breast cancer: a study of the NCIC Clinical Trials Group [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A546
72. 72. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Rad Oncol Biol Phys 1994; 29: 747-54
73. 73. Büntzel J, Glatzel M, Fröhlich D, et al. Intensification of radiochemotherapy with amifostine in head and neck cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A1555
74. 74. Kataoka Y, Basic I, Perrin J, et al. Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neurons and 60Co gamma-rays in mice. Int J Radiat Biol 1992; 61: 387-92
75. 75. Kataoka Y, Perrin J, Hunter N, et al. Antimutagenic effects of amifostine: clinical implications. Semin Oncol 1996; 4 Suppl. 8: 53-7
76. 76. Grdina DJ, Shigematsu N, Dale P, et al. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995; 16: 767-74
77. 77. Liu SC, Murley JS, Woloschak G, et al. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 1997; 18: 2457-9
78. 78. Bennett CL, Golub RM, Calhoun EA, et al. Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. Int J Gynecol Cancer 1998; 8: 64-72